Patheon to Exhibit Biologics Services and Expertise at 2015 BIO International Convention

Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma industries, will showcase ways to accelerate biologic process development and funding options for biopharmaceutical programs at the BIO International Convention in Philadelphia, from Tuesday, June 16, to Wednesday, June 17.   

Two of Patheon’s biologics rapid development and scale-up experts, Matt Caple, scientific director, cell culture development, and Tertia Dex, director, business development, will offer exclusive scientific  information sessions at booth #1374. Caple will discuss ways to reduce biologic process development timelines, while Dex will speak on non-dilutive funding for biopharmaceutical programs and how companies can receive up to 45 percent cash back through the Australian research and development tax incentive.

Sessions will take place between 9:30 a.m. and 11:30 a.m. on Tuesday, and 2:30 p.m. and 3:30 p.m. on Wednesday. To view specific session times and schedule a meeting with Dex or Caple, visit

Patheon will also host a reception for the Premier and other government officials from Queensland, Australia, on June 14, prior to the convention’s kick off. Patheon’s facility in Brisbane, Australia, was awarded the 2014 International Society of Pharmaceutical Engineering (ISPE) Facility of the Year Award for process innovation, and supports the company’s biologics business and global footprint. 

Patheon Media Relations

Tel: +1 (919) 210-0986

Email: or

About Patheon
Patheon, a business unit of DPx Holdings B.V., delivers a combination of unrivaled quality, reliability and compliance, with a reputation for scientific and technical excellence to customers in the pharmaceutical and biopharma sector. A leading global provider with more than 8,000 employees worldwide, Patheon has a comprehensive set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at any stage of the pharmaceutical development cycle. For more information, visit